View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 31, 2020

Aptorum and Covar explore repurposed drugs for coronavirus

Aptorum Group is set to choose at least three repurposed drug candidates for Covid-19 treatment, out of nearly 2,600 approved small drug molecules screened using its Smart-ACT drug discovery platform.

Aptorum Group is set to choose at least three repurposed drug candidates for Covid-19 treatment, out of nearly 2,600 approved small drug molecules screened using its Smart-ACT drug discovery platform.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The company has partnered with Covar Pharmaceuticals and signed an agreement with the University of Hong Kong’s microbiology department for preclinical testing of the selected drugs.

Following successful tests, the company will obtain regulatory approval for human clinical trials.

Aptorum Group CEO Ian Huen said: “Despite a growing number of both established and early-stage pharmaceutical companies rushing to develop vaccine-based therapies for Covid-19, we believe there is a need to tackle this disease multi-dimensionally and urgently.

“In order to accelerate development, our aim is to identify candidates from already approved drugs, that have established safety, toxicity and pharmacokinetic clinical profiles, to be repurposed for treatment of Covid-19.”

The company will specifically work on at least three small molecule drugs, SACT-COV19, with potential to target 3CL-Protease and RNA dependent RNA Polymerase enzymes linked to the novel coronavirus replication.

3CL-Protease is associated with viral replication and transcription via proteolytic processing, while RDRP catalyses the viral RNA replication.

The selected candidates will be subjected to preclinical testing to validate efficacy against SARS-CoV-2, which causes Covid-19 infection.

In addition to Covar and University of Hong Kong collaborations, Aptorum plans to form more alliances worldwide to advance its SACT-COV19 development.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology